| Source: |
| Type: Protein Coding gene |
| Beclin 1, an autophagy and haploinsufficient tumor-suppressor protein, is frequently monoallelically deleted in breast and ovarian cancers. However, the precise mechanisms by which Beclin 1 inhibits tumor growth remain largely unknown. A key biomarker of autophagy is Beclin-1. Beclin-1 stimulates LC3-I’s lipidation to produce LC3-II, which localizes to the autophagosome membrane to activate the development of autophagosomes. -BECN1 = the official gene symbol (human gene name) -Beclin-1 = the protein name encoded by the BECN1 gene BECN1 - Beclin 1 Abbreviation: BECN1, Beclin 1 Alternative Names: ATG6, VPS30 Type: Autophagy regulator / class III PI3K complex component Function: Beclin 1 is a core component of the VPS34/class III PI3K complex and promotes phosphatidylinositol-3-phosphate production required for autophagosome nucleation and membrane trafficking. Cancer: ↕ Context-dependent. Reduced BECN1 expression can contribute to tumor initiation and genomic instability, supporting a tumor-suppressive role in some tissues. However, established cancers can also exploit Beclin 1-dependent autophagy for survival under metabolic and therapeutic stress. |
| Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer. Nanog is highly expressed in CSCs compared to normal cells [93–97] HIF-1↑ |
| 1580- | Citrate, | Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | PC, | NA | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | WPMY-1 |
| 1962- | GamB, | HCQ, | Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species |
| - | in-vitro, | PC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:21 Cells:% prod#:% Target#:30 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid